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Abstract
Introduction: Multiple distinct tumors arising in a single individual or within members of a family
raise the suspicion of a genetic susceptibility disorder.
Case presentation: We present the case of a 52-year-old Caucasian woman diagnosed with
sebaceous gland carcinoma of the eyelid, followed several years later with subsequent diagnoses of
breast cancer and papillary carcinoma of the thyroid. Although the patient was also exposed to
radiation from a pipe used in the oil field industry, the constellation of neoplasms in this patient
suggests the manifestation of a known hereditary susceptibility cancer syndrome. However, testing
for the most likely candidates such as Muir-Torre and Cowden syndrome proved negative.
Conclusion: We propose that our patient’s clustering of neoplasms either represents a novel
cancer susceptibility disorder, of which sebaceous gland carcinoma is a characteristic feature, or is a
variant of the Muir-Torre syndrome.
Introduction
Multiple distinct tumors arising in a single individual or
within members of a family raise the suspicion of a genetic
susceptibility disorder [1,2]. Tumor suppressor genes, such
as PTEN in Cowden syndrome and BRCA1/2 in breast
cancer, function by eliciting apoptosis and G1 cycle arrest.
However, expression and tissue-specific splicing may lead
to the differential expression of splice variants (SVs) with
subsequent downstream signaling consequences. SVs
resulting from alterations in the splicing of cancer-related
genes could represent novel cases of familiar syndromes
that do not reveal classic mutations.
Page 1 of 6
(page number not for citation purposes)
The diagnosis of sebaceous gland carcinoma can represent
a marker of an associated heritable disorder, and some
authors recommend patients be evaluated for other
visceral malignancies [3]. Additionally, prompt diagnosis
enables routine surveillance of occult cancers, identifica-
tion of low-grade tumors that would be more responsive
to treatment, and identification of family members at risk
for developing cancer.
Case presentation
A 52-year-old Caucasian woman from Mississippi with
a history of sebaceous carcinoma of the left lower eyelid,
breast cancer of the right breast (ER+/PR+/HER2+), and
papillary thyroid cancer treated by total thyroidectomy
and radioactive iodine ablation (49.5 mCi) was referred to
our clinic for follow-up evaluation. Sebaceous gland
carcinoma of the eye was diagnosed when the patient
was 43-years-old and surgically treated at a hospital in
Pennsylvania. She was then diagnosed with multifocal
ductal carcinoma in situ of the right breast (Figure 1) in
2004 (T2N0M0), for which testing showed to be ER/PR+
as well as HER2+.
Following simple unilateral mastectomy, she initially
underwent eight cycles of chemotherapy and tamoxifen
treatment, but stopped taking tamoxifen secondary to
fears of developing endometrial cancer in 2006. At that
time, her hormone levels were checked revealing a low
estradiol level (13.9 pg/ml) and an appropriately elevated
follicle-stimulating hormone (FSH) (63 mIU/ml), indica-
tive of menopause.
A mammogram from 2008 was unremarkable for recur-
rent cancer and she denied any vaginal bleeding. In 2005,
a papillary thyroid carcinoma (size: 0.6 cm) was diag-
nosed after she had been found to have a thyroid nodule
on routine ultrasound for which a right lobectomy was
initially performed, but later followed by a total thyroi-
dectomy in light of her multiple prior cancers.
She subsequently received ablative therapy with 49.5 mCi
of 131Iodine in 2006. Since that time, she has remained
asymptomatic and is taking daily calcium tablets as well as
150 mcg of thyroxine. Serum thyroglobulin levels had
been undetectable (<0.1 ng/ml) while thyroglobulin
antibodies were measured at 12 IU/ml (normal, <4.0),
and thyroid stimulating hormone (TSH) at 0.006 mcU/ml
(0.23 to 4.0 mcU/ml). Sonographic examinations of
her neck had been non-suspicious for recurrent cancer.
Given her postmenopausal and iatrogenically-induced
hyperthyroid state, she underwent a bone mineral density
study that revealed osteopenia at the spine and the femur
(T-score was minus 1.1). Her 25-hydroxy vitamin D level
was normal at 41 ng/ml.
The patient's family history was positive for breast cancer
in her mother and maternal aunt. One of the patient’s
paternal first degree cousins suffered from an inoperable
brain tumor, and a male and a female paternal second
degree cousin had breast cancer. However, her family
history was negative for colon cancer, endometrial or
ovarian cancers, thyroid cancer, or any other cancers.
The patient recollected that her husband, who died of
colon cancer, had been gainfully employed welding and
cutting pipe that was previously used in the oil field
industry. She further remembered being proximate to the
pipe on multiple occasions, when she was helping her
husband cut and weld sections, with resultant fume
inhalation. After his death, she was unable to sell the
pipe because it was determined to be too radioactive from
its prior use in the oil field to be sold on the open market.
The determination of radioactivity was made using a
Geiger counter; however, the type of radiation was not
determined.
Based on her personal and family history of multiple
cancers, the patient underwent genetic testing for Cowden
syndrome (PTEN gene testing for mutations in exons 1 to
9 was negative), screening colonoscopy (negative) to
exclude Muir-Torre syndrome, hereditary nonpolyposis
colorectal cancer (HNPCC) or a variant of HNPCC, and
immunohistochemistry (IHC)/microsatellite instability
(MSI) testing on her breast cancer specimen for HNPCC
(IHC: normal pattern for hMLH1, hMSH2, hMSH6,
hPMS2; MSI: BAT25, BAT26, BAT40, BAT34c mononu-
cleotide repeats, D17s250, D5s346, D18s55, D10s197,
MycL, ACTC dinucleotide). We could not rule out a PTEN
promoter mutation, because this was not tested. Given
Figure 1. Infiltrating ductal carcinoma of the right breast,
Grade 2. H & E stain, original magnification 400x.
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a Manchester score of 5-7 for BRCA2 with a less than 5%
chance of finding a BRCA2 mutation, mutation analysis in
BRCA1 or BRCA2 was not pursued.
Discussion
Sebaceous gland carcinoma is a rare neoplasm arising from
the Meibomian glands, Zeis glands, or sebaceous glands of
the caruncle and eyebrow, and represents 1-6%of all eyelid
malignancies [4,5]. Themedian age at diagnosis is 72 years,
with most diagnoses prior to 30 years of age revealing a
history of radiation exposure [4,6]. Moreover, among
individuals diagnosed with sebaceous gland carcinoma,
the incidence of one ormore primary visceral malignancies
has been noted to be as high as 42% [7].
In their report, Finan and Connolly [7], listed thyroid
adenomas, uterine fibroids, and benign renal cysts as less
common findings. Papillary thyroid carcinoma (PTC) is
the most common thyroid malignancy worldwide, com-
prising 50% to 70% of differentiated follicular cell thyroid
carcinomas [8-10]. PTC is strongly associated with prior
irradiation to the head and neck, likely resulting in
chromosome breakage and rearrangement with fusion of
the RET tyrosine kinase domain to various breakpoint
sites, clearly demonstrated in post-Chernobyl thyroid
tumors [11,12]. Familial clustering of PTC is well
recognized and family studies have revealed autosomal
dominant transmission [13]. The high incidence of PTC
in patients with adenomatous polyposis and Cowden
syndrome (the multiple hamartoma syndrome) suggests a
shared set of susceptibility genes. The genetic differential
diagnosis for papillary thyroid carcinoma is shown in
Table 1.
The strong family history of breast neoplasms in our
patient further suggests an increased susceptibility to
cancer. Breast cancer is the most common cancer in
women and has been associated with a number of specific
genetic mutations, namely BRCA1/2, which accounts for
approximately 5% of reported cases [14]. Less frequently
implicated in breast cancer are PTEN in Cowden syn-
drome, MLH1 and MSH2 in Muir-Torre, and STK11 in
Peutz-Jeghers syndrome [15-17].
Our patient presented with multiple malignant neoplasms
including sebaceous gland carcinoma, papillary thyroid
carcinoma, and breast cancer. Her mother who died at age
73 and maternal aunt who died at age 67 with a diagnosis
of breast at around age 50, were both diagnosed with
breast cancer, but both did not suffer any of the other
neoplasms that were present in our patient. The clustering
of visceral malignancies with sebaceous carcinoma in our
patient is a unique occurrence and strongly suggests the
likelihood of an underlying cancer susceptibility disorder,
perhaps an under-recognized manifestation or variant of
the Muir-Torre syndrome.
We considered whether these observations might be
explained in the context of a known genetic cancer
susceptibility disorder and felt that Muir-Torre syndrome
(MTS), Cowden syndrome (CS), and Carney complex
(CRC) were the most likely candidates, although none
completely accounts for the pattern of neoplasms in this
patient.
Muir-Torre syndrome (MTS) is an autosomal dominant
disorder characterized by sebaceous gland carcinoma and
one or more internal visceral malignancies (Table 2). The
etiology of this disorder is thought to result from a
mutation in the mismatch DNA repair genes MSH-2 and
MLH-1, supported by the finding of microsatellite
instability in tumors of some patients [18,19]. However,
one study shows that 31% of patients with MTS tumors
exhibited no microsatellite instability, which suggests the
existence of at least two variants of MTS with different
molecular mechanisms [20]. MTS has also been described
in the setting of MYH-related attenuated polyposis,
resulting from a mutation in the MYH gene that caused
aberrations in base excision repair. However, its role in the
development of cutaneous sebaceous carcinogenesis is
unclear [21]. Patients with MTS often have colonic polyps
and adenomas, but neither is necessary to make the
diagnosis. The most commonly identified neoplasms in
MTS are shown in Table 3. Conventional testing on the
breast cancer specimen of our patient was indicative of
normal DNA mismatch repair function within the tumor.
We did not perform mutation analysis of MSH-2 and
MLH-1.
Cowden syndrome (CS) is an autosomal dominant
disorder distinguished by pathognomonic mucocuta-
neous lesions such as facial trichilemmomas, acral
keratoses and papillomatosis; hamartomatous polyps,
and internal visceral malignancies including breast and
thyroid cancer. The causative mutation in this syndrome
Table 1. Genetic Differential Diagnosis of Thyroid Cancer Associated
Syndromes
Histology Syndrome Association Gene (if known)
Medullary MEN2 RET
Follicular Cowden Syndrome PTEN
Werner Syndrome WRN
Papillary Familial Adenomatous Polyposis APC
Cowden Syndrome PTEN
Carney Complex PRKAR1A
Familial Nonmedullary Thyroid Cancer
Syndrome
Familial Papillary Thyroid Carcinoma
Adapted from: Weber F, Eng C. Update on the Molecular Diagnosis
of Endocrine Tumors: Toward–omics-Based Personalized Healthcare?
J Clin Endocrinol Metab 2008, 93(4):1097-1104.
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involves the PTEN tumor suppressor gene, resulting in an
unregulated progression through the G1 phase of the cell
cycle.
Our patient had breast and thyroid cancer, but her lack of
hamartomatous polyps and the presence of a sebaceous
carcinoma cannot be readily explained in the framework
of this syndrome. Furthermore, there have been no reports
of sebaceous carcinoma in a patient with CS. PTC is a
cancer strongly linked with radiation exposure to the head
and neck and the proximity of the sebaceous carcinoma
suggests that both could have resulted from a single field
of exposure, in this case the radioactive piping that the
patient was exposed to. Commercial testing for germline
mutations in PTEN failed to show any in exons 1-9.
However, a mutation is identified in only 80% of patients
who meet clinical criteria [22,23]. On the other hand,
recent data suggest that germline sequence variants in
various tumor suppressor and/or oncogenes may coopera-
tively promote tumorigenesis of various tumor types
including thyroid cancer [24-32].
Meanwhile, Carney complex is an autosomal dominant
disorder that leads to endocrine gland tumors and/or
hyperfunctioning commonly involving the pituitary,
adrenal, and thyroid glands, as well as myxomas (skin,
heart, and breast) and lentiginosis in select areas of the
skin. The causative mutation involves the regulatory
subunit of protein kinase receptor 1A (PRKAR1A), which
results in nonsense-mediated decay of the transcript and
altered protein kinase A signaling [13]. Again, the presence
of breast and thyroid neoplasms is suspect, but sebaceous
gland carcinoma has not been described in the setting of
Carney complex. We did not test for a germline mutation
of the PRKAR1A gene, which is detectable in 50-65% of
cases.
The field of genomics has provided new insight on the role
that splicing and other mRNA processing mechanisms
serve in the regulation of gene function. Numerous
examples of alterations in splicing and differential expres-
sion of SVs and their role in various sporadic cancers have
been reported [33-37]. Many of the genes involved in
cancer susceptibility syndromes (PTEN, APC, MSH-2) are
ubiquitously expressed and tissue-specific splicing may
lead to differential expression of SVs, which may suggest
different roles for different SVs in different tissues. In fact,
one study identified SVs of PTEN that were expressed
differentially in heritable cancer, sporadic cancer, and
controls. It is believed that the nonlinear, tissue-specific
expression of these SVs exert varying effects at the
functional or regulatory level [38].
The implication of such research becomes especially
important when considering that similar gene regulation
and inactivation occurs in the inherited cancer syndromes,
even in the absence of identifiable gene mutations. This
may in part explain the relatively low sensitivity of modern
laboratory techniques that rely heavily on isolating specific
mutation sequences. For instance, abnormalities in the
promoter region of a gene could be missed or deletions of
one or more exons on one allele.
Additionally, measurement of mRNA content in periph-
eral blood may aid diagnosis as well as provide novel
biomarkers for the identification of certain types of cancer,
possibly circumventing the need for traditionally invasive
techniques such as FNA, for example, in thyroid cancer
(13). Furthermore, such discoveries could pave the way
for targeting anti-apoptotic SVs to lower the apoptotic
threshold of a tumor cell, thereby increasing the efficacy
of chemotherapy drugs. Despite the emerging evidence
linking mRNA level regulation and carcinogenesis, there
is limited information regarding its role in many of the
well-characterized familial cancer syndromes. Very few SVs
have been identified and, unfortunately, many of those
that have been identified were not attributed with any
functional significance [38].
Conclusions
Our patient, who had an unusual clustering of sebaceous
gland carcinoma and internal malignancies, represents
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a unique clinical case. The most likely explanation would
be that of either a single, unifying genetic cause resulting
from a still undiscovered germline mutation, or coopera-
tive tumorigenesis by germline sequence variants in
various genes that play a role in tumor development.
The history of radiation exposure was arguably the
environmental catalyst for malignant transformation in
this patient with an underlying genetic susceptibility. In
the future, advancements in the field of genomics may
allow further elucidation of the role of SVs in cancer
susceptibility syndromes lacking identifiable genetic
mutations.
We speculate that this patient’s clustering of neoplasms
represents a novel cancer susceptibility disorder, of which
sebaceous gland carcinoma is a characteristic feature. This
hypothesis cannot be tested on the basis of a single case
report; therefore, we await further contributions from
other clinical investigators.
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